DanCann Pharma A/S approved for listing at Spotlight Stock Market
DanCann Pharma is a Danish pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.
DanCann Pharma was established due to the poor access for cannabinoid-based drugs and pharmaceuticals, where people instead searched for the uncontrolled illegal market. For that reason, DanCann Pharma today works with the mission of securing access to treatments with quality assured cannabinoid substance. DanCann Pharma’s businessplan has several tracks, including: Imports, R&D, and own in-house production. The company has permission from the Danish Medicine Agency (”DMA”) to handle euphoriant substances and to handle and cultivate cannabis for medical use under the Development Scheme. The Company is currently in the process of establishing one of the most advanced and efficient cannabis cultivation sites in Europe.
DanCann Pharma are developing indoor production facilities for a factory with vertical aeroponics systems – a cultivation technique developed by NASA – in closed and hygienic climate-controlled premises for soil-free (no contaminants) and pesticide-free cultivation for production of pharmaceutical cannabis- and cannabinoids. Through an easy interface, it is possible to control and monitor all elements during production such as temperature, humidity, light, watering, and other factors, all of which can affect quality, uniformity, and strength.
”We see our current position as an advantage. We have not "rushed" our business, but carefully considered how to approach this task. This is reflected in all the choices we, as an organization, make to ultimately ensure patient safety and satisfying results for our investors. With that said, an exciting time awaits us.”
- Jeppe Krog Rasmussen
Founder, CEO & Board Member, DanCann Pharma
Listing at Spotlight Stock Market
Both shares and warrants in DanCann Pharma A/S has been approved for listing at Spotlight Stock Market. The first day of trading is planned to November 12, 2020. The approval is given under the condition that the company raises the minimum limit and that the company obtains a sufficient number of shareholders in accordance with Spotlight Stock Market’s listing agreement in the upcoming IPO.
Information about the share
Short name: DANCAN
ISIN: DK0061410487
First day of trading: November 12, 2020
Information about the warrants
Short name: DANCAN TO 1
ISIN: DK0061410560
First day of trading: November 12, 2020
The company prospectus will shortly be published at www.spotlightstockmarket.com
For more information, please contact:
Oskar Wollert
Head of Listing, Spotlight Stock Market
+46 8 511 68 008
listing@spotlightstockmarket.com